These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

225 related items for PubMed ID: 17923619

  • 21. Immortal time bias in the study of effectiveness of interferon-beta in multiple sclerosis.
    Renoux C, Suissa S.
    Ann Neurol; 2008 Jul; 64(1):109-10; author reply 110. PubMed ID: 18668635
    [No Abstract] [Full Text] [Related]

  • 22. Effect of anti-IFN{beta} antibodies on MRI lesions of MS patients in the BECOME study.
    Pachner AR, Cadavid D, Wolansky L, Skurnick J.
    Neurology; 2009 Nov 03; 73(18):1485-92. PubMed ID: 19884576
    [Abstract] [Full Text] [Related]

  • 23. Strategies to treat and prevent the development of neutralizing anti-interferon-beta antibodies.
    Giovannoni G.
    Neurology; 2003 Nov 11; 61(9 Suppl 5):S13-7. PubMed ID: 14610104
    [Abstract] [Full Text] [Related]

  • 24. Neutralizing antibodies to interferon beta in multiple sclerosis: analytical evaluation for validation of a cytopathic effect assay.
    Massart C, Gibassier J, Oger J, Le Page E, Edan G.
    Clin Chim Acta; 2007 Feb 11; 377(1-2):185-91. PubMed ID: 17123498
    [Abstract] [Full Text] [Related]

  • 25. Confounders in natural history of interferon-beta-treated relapsing multiple sclerosis.
    Gout O.
    Ann Neurol; 2008 Jan 11; 63(1):126; author reply 126-7. PubMed ID: 17702028
    [No Abstract] [Full Text] [Related]

  • 26. Development of resistance to biologic therapies with reference to IFN-β.
    Farrell RA, Marta M, Gaeguta AJ, Souslova V, Giovannoni G, Creeke PI.
    Rheumatology (Oxford); 2012 Apr 11; 51(4):590-9. PubMed ID: 22258390
    [Abstract] [Full Text] [Related]

  • 27. Assessment: symptomatic treatment for muscle cramps (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
    Rison RA.
    Neurology; 2010 Oct 12; 75(15):1397; author reply 1398-9. PubMed ID: 20960668
    [No Abstract] [Full Text] [Related]

  • 28. Assessment: symptomatic treatment for muscle cramps (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
    Mauskop A.
    Neurology; 2010 Oct 12; 75(15):1397; author reply 1398-9. PubMed ID: 20938035
    [No Abstract] [Full Text] [Related]

  • 29. Practice parameter: diagnostic assessment of the child with cerebral palsy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society.
    Mink JW, Jenkins ME.
    Neurology; 2004 Nov 23; 63(10):1985-6; author reply 1985-6. PubMed ID: 15557540
    [No Abstract] [Full Text] [Related]

  • 30. Multiple sclerosis: relating MxA transcription to anti-interferon-beta-neutralizing antibodies.
    Hoffmann LA, Krumbholz M, Faber H, Kuempfel T, Starck M, Pöllmann W, Meinl E, Hohlfeld R.
    Neurology; 2007 Mar 20; 68(12):958-9. PubMed ID: 17372138
    [No Abstract] [Full Text] [Related]

  • 31. Neutralizing antibodies to interferon.
    Noronha A.
    Neurology; 2007 Jun 12; 68(24 Suppl 4):S16-22. PubMed ID: 17562846
    [Abstract] [Full Text] [Related]

  • 32. Neutralising antibodies against interferon beta in multiple sclerosis.
    Giovannoni G, Deisenhammer F.
    Lancet; 2004 Jan 10; 363(9403):166-7; author reply 168-9. PubMed ID: 14726177
    [No Abstract] [Full Text] [Related]

  • 33. Interferon-beta therapy for MS: the dilemma of having choices.
    Khan O.
    J Neurol Sci; 2004 Jul 15; 222(1-2):1. PubMed ID: 15240187
    [No Abstract] [Full Text] [Related]

  • 34. Assessment: use of epidural steroid injections to treat radicular lumbosacral pain: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
    Jordan SE.
    Neurology; 2007 Sep 11; 69(11):1191; author reply 1191-2. PubMed ID: 17846420
    [No Abstract] [Full Text] [Related]

  • 35. Practice parameter: diagnostic assessment of the child with cerebral palsy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society.
    Whelan MA.
    Neurology; 2004 Nov 23; 63(10):1985-6; author reply 1985-6. PubMed ID: 15568275
    [No Abstract] [Full Text] [Related]

  • 36. Biomarkers for interferon response in MS: are we there yet?
    Rudick RA, Ransohoff RM.
    Neurology; 2008 Mar 25; 70(13 Pt 2):1069-70. PubMed ID: 18362268
    [No Abstract] [Full Text] [Related]

  • 37. Neutralizing antibodies against interferon-β do not predispose antibodies against natalizumab.
    Sørensen PS, Koch-Henriksen N, Jensen PE.
    Neurology; 2011 Feb 22; 76(8):759-60. PubMed ID: 21339504
    [No Abstract] [Full Text] [Related]

  • 38. Significance of neutralizing antibodies to interferon beta during treatment of multiple sclerosis: expert opinions based on the Proceedings of an International Consensus Conference.
    Hartung HP, Munschauer F, Schellekens H.
    Eur J Neurol; 2005 Aug 22; 12(8):588-601. PubMed ID: 16053466
    [Abstract] [Full Text] [Related]

  • 39. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.
    Schwid SR, Panitch HS.
    Clin Ther; 2007 Sep 22; 29(9):2031-48. PubMed ID: 18035202
    [Abstract] [Full Text] [Related]

  • 40. Commentary on neutralizing antibodies to interferon beta in patients with multiple sclerosis.
    Whitaker JN.
    Arch Neurol; 2001 Aug 22; 58(8):1301. PubMed ID: 11493175
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.